Key Capital Management’s Moderna MRNA Stock Holding History

Key Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05K	Buy	+15	New	+$776	﹤0.01%	651

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Key Capital Management's MRNA Position: Q2 2026 in Review

Key Capital Management opened a new position in Moderna (MRNA) in Q2 2026: 15 shares worth $1.05K. The stake represents ﹤0.01% of the portfolio and ranks #651 among its holdings.

362 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Key Capital Management held 15 shares of Moderna worth $1.05K as of Q2 2026.
Moderna was a new Key Capital Management position in Q2 2026.
Moderna made up ﹤0.01% of Key Capital Management's portfolio in Q2 2026, its #651 holding.
362 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Key Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.